在 @myESMO #ESMO26 公布的最新一期临床数据显示，INCB123667 联合 bevacizumab 用于既往接受过大量治疗、cyclin E1 过度表达的铂类耐药卵巢癌患者，缓解率为 48%。
研究结果还显示，既往接受过 PARP 抑制剂和 bevacizumab 治疗的患者也出现了缓解。
阅读更多：https://www.onclive.com/view/incb123667-plus-bevacizumab-shows-antitumor-activity-in-recurrent-epithelial-ovarian-cancer #gyncsm #medtwitter #oncology
175 浏览 · 1 赞 · 2 转发 · 0 回复
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.org来源：OncLive.com · x.com